Instrument Inactif

Autres langues IceCure Medical Ltd TEL AVIV STOCK EXCHANGE

Actions

ICCM

IL0011224156

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

IceCure Medical : Company Presentation	23/04
IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate, Data Submitted to FDA Requesting Marketing Authorization	16/04
IceCure Medical Seeks FDA Nod For ProSense to Treat Early-Stage Breast Cancer	15/04
IceCure Medical Ltd Submits Final Data to the U.S. Food and Drug Administration Requesting Marketing Authorization for ProSense	15/04
IceCure Submits FDA Regulatory Filing for New XSense Cryoablation System with Cryoprobes	03/04
IceCure Medical Ltd Reports Earnings Results for the Full Year Ended December 31, 2023	03/04
IceCure Medical Seeks FDA Clearance for Cryoablation Technology	02/04
IceCure Submits FDA Regulatory Filing for New XSense™ Cryoablation System with Cryoprobes	02/04
Icecure Submits FDA Regulatory Filing for New Xsense? Cryoablation System with Cryoprobes	02/04
IceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024	27/03
IceCure Medical Reports Positive Topline Results from ICE3 Cryoablation Breast Cancer Study	20/03
IceCure Medical Reports Positive Topline Results From ICE3 Cryoablation Breast Cancer Study: Achievement of 96.39% Recurrence Free Rate Brings Company One Step Closer to Providing Women a Non-Surgical Alternative to Lumpectomy	19/03
IceCure Medical Ltd. Reports Positive Topline Results from ICE3 Cryoablation Breast Cancer Study	19/03
IceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogen Flow Control to Optimize Patient Outcomes	12/03
IceCure Medical to Present at 34th Annual Oppenheimer Healthcare MedTech and Services Conference	08/03
IceCure Medical to Present at 34th Annual Oppenheimer Healthcare MedTech & Services Conference	07/03
IceCure's ProSense® a Promising Alternative Treatment for Extra-Pelvis Endometriosis: Independent Study Presented at ECR 2024	04/03
IceCure Medical Ltd. Announces Results from an Independent Study	04/03
Fourth BRIIT Conference in India Features IceCure's ProSense in Breast Cancer Imaging and Interventions Workshop	28/02
Study Using IceCure's ProSense Treatment Results in 100% Tumor Reduction in Early-Stage Breast Cancer	27/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues IceCure Medical Ltd TEL AVIV STOCK EXCHANGE

Actions

ICCM

IL0011224156

Autres langues

Filtres